Navigation Links
PharmAthene Reports First Quarter 2008 Financial Results
Date:5/13/2008

ommence the first Phase I safety study in humans, which is expected to

be completed early next year.

Financial Results

PharmAthene received revenues of $5.8 million for the three months ended March 31, 2008 compared to $3.0 million for the same period in 2007. These revenues consist primarily of contract and grant funding from the U.S. government for the development of the Company's chemical nerve agent prophylaxis, Protexia(R).

PharmAthene's research and development expenses were $5.9 million and $3.1 million for the three months ended March 31, 2008 and 2007, respectively. These expenses resulted primarily from research and development activities related to the development of Valortim(TM) for protection against and treatment of inhalation anthrax, and the development of Protexia(R) for treatment of nerve agent poisoning. Research and development expense increased $2.8 million for the three months ended March 31, 2008 as compared to the same period in 2007, primarily as a result of increased process development and manufacturing activities for both Valortim(TM) and Protexia(R), and employee-related expenses including stock compensation expense.

General and administrative expenses for the Company were $4.7 million and $2.5 million respectively, for the three months ended March 31, 2008 and 2007. Expenses associated with general and administrative functions for the Company increased $2.2 million primarily due to increased employee costs, increased stock compensation expense and additional costs associated with the Company's compliance and legal functions.

PharmAthene's net loss for the first quarter of 2008 was $5.0 million or $0.23 per share.

As of March 31, 2008, available cash, cash equivalents and short term investments were $25.7 million, after giving effect to $20.0 million in restricted cash.

Conference Call Information

PharmAthene management will host a conference call to discuss the Company's f
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
2. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
3. PharmAthene Reports Year-End 2007 Financial Results
4. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
5. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
6. PharmAthene to Delay Release of Full Year 2007 Financial Results
7. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
10. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
11. PharmAthene to Present at the BIO CEO & Investor Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , September 29, 2014 Atox ... severe infections, today announced that the Biomedical Advanced Research ... Bio with a contract valued up to $24 million ... treat Necrotizing Soft Tissue Infections (NSTI) and potentially infections ... in sepsis. BARDA awarded the contract to ...
(Date:9/29/2014)... , Sept. 29, 2014  Xcenda, the strategic ... global pharmaceutical sourcing and distribution service companies, recently ... consumption. This research was analyzed in an economic ... associated with an increase in life years and ... at population-level coffee consumption across the ...
(Date:9/28/2014)... Modality Solutions, a company ... highly regulated industries, is pleased to announce Consulting ... Transport Simulation Laboratoryâ„¢ software at the 12th Annual ... Forum in Boston, September 29 through October 3. ... software on October 2, day two of the ...
(Date:9/27/2014)... available in German . ... only used for precisely surveying the surface topology of ... is done by exciting the atoms to fluoresce under ... This secondary emission provides information about the location and ... precise. However, the lighter elements of the periodic table ...
Breaking Biology Technology:Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2Coffee Consumption May Increase Survival and Reduce Healthcare Costs 2Coffee Consumption May Increase Survival and Reduce Healthcare Costs 3Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 2Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 3'Multi-spectra glasses' for scanning electron microscopy 2
... Pharmaceuticals,Inc. (NYSE: BRL ) today confirmed that ... of the patents listed by Amgen Inc. in,connection ... 90mg., Barr,s Abbreviated New Drug Application (ANDA) ... product was received as acceptable,for filing by the ...
... are to be used in clinical trials ... on a path to finally cure diabetes, ... recently declared its commitment to support Spring Point,Project, a Minnesota non-profit ... of islet tissue for,diabetes care., (Logo: http://www.newscom.com/cgi-bin/prnh/20071214/CLF057LOGO-b ), ...
... as an Antipsychotic Agent with Less Potential for ... Weight Gain and Metabolic Risks, SAN DIEGO, July ... announced that the United States Patent and,Trademark Office (USPTO) ... would provide broad coverage for a pharmaceutical,composition of zonisamide ...
Cached Biology Technology:Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg 2Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg 3Spring Point Project Gains Support of Lions Clubs 2Spring Point Project Gains Support of Lions Clubs 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 2OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 4
(Date:9/29/2014)... order to support the world,s needs to make ... more, new and more efficient catalytic materials and ... including several from Wayne State University, is tackling ... grant from the National Science Foundation. , The ... Multicomponent Materials for Electrocatalytic Cascade Reactions," was to ...
(Date:9/29/2014)... received a five-year, $6 million grant for clinical ... and development of safe and effective treatments for ... the National Institutes of Health, National Institute on ... Medication Development for Cocaine Use Disorder to oversee ... decisions on moving forward with more expensive large-scale ...
(Date:9/29/2014)... review article published online in Behavioral Brain Research ... the brain as a result of chronic alcohol exposure ... , Clinical assessments and research indicate that individuals ... sleep. This can occur when people are actively drinking, ... are abstaining. , "Sleep-wake disturbances can last for ...
Breaking Biology News(10 mins):Wayne State research aims to develop new, more efficient catalytic materials 2New VCU center to target cocaine addiction 2
... 14, 2012 The latest episode in the American ... podcast series describes the development of a new test ... Amid concerns about the threat of terrorist attacks, ... and other nations. One such team has developed a ...
... Irvine researchers have discovered how Salmonella , a bacterium ... in humans, thrives in the digestive tract despite the immune ... explain why Salmonella is difficult to eradicate and ... with Salmonella suffer from diarrhea, fever and abdominal ...
... A parking lot at the edge of the University ... emerging concern for the environment and human health. ... journal Environmental Science & Technology , has found that ... lots throughout the nation, has significant health and ecosystem implications. ...
Cached Biology News:New test could help track down and prosecute terrorists 2UCI-led study uncovers how Salmonella avoids the body's immune response 2UNH research adds to mounting evidence against popular pavement sealcoat 2